Individual approach in choosing second-line targeted therapy for metastatic renal cell carcinoma
https://doi.org/10.17650/1726-9776-2018-14-2-68-78
Abstract
Renal cell carcinoma (RCC) is one of the most common genitourinary malignancies worldwide. Approximately 25–30 % of newly diagnosed patients have metastatic RCC (mRCC), whereas in 20–30 % of cases, dissemination occurs after radical surgical treatment. The development of targeted and immunooncological agents in recent years significantly increased survival in patients with mRCC. However, clinicians faced a problem of choosing an optimal therapeutic regimen to achieve maximum effectiveness of the treatment. This article discusses the choice of second-line drugs for mRCC, advantages of axitinib and its optimal dosage, and efficacy of sunitinib depending on the disease prognosis.
About the Authors
B. Ya. Alekseev
National Medical Research Center of Radiology, Ministry of Health of Russia
Russian Federation
32nd Botkinskiy Proezd, Moscow 125284
Russian Federation
32nd Botkinskiy Proezd, Moscow 125284
I. M. Shevchuk
National Medical Research Center of Radiology, Ministry of Health of Russia
Russian Federation
32nd Botkinskiy Proezd, Moscow 125284
Russian Federation
32nd Botkinskiy Proezd, Moscow 125284
A. D. Kaprin
National Medical Research Center of Radiology, Ministry of Health of Russia
Russian Federation
32nd Botkinskiy Proezd, Moscow 125284
Russian Federation
32nd Botkinskiy Proezd, Moscow 125284
References
1. International Agency for Research on Cancer. The GLOBOCAN project: cancer incidence and mortality worldwide in 2012. Available at: http://globocan.iarc.fr/Pages/fact_sheets_population.aspx.
2. Malignant tumors in Russia in 2016 (morbidity and mortality). Eds.: А.D. Kaprin, V.V. Starinskiy, G.V. Petrova. Moscow: MNIOI im. P.A. Gertsena – filial FGBU “NMITSR” Minzdrava Rossii, 2018. 250 p. (In Russ.).
3. Surveillance, Epidemiology, and End Results Program. National Cancer Institute. Cancer stat facts: kidney and renal pelvis cancer. Available at: https://seer.cancer.gov/statfacts/html/kidrp.html.
4. Campbell M.T., Shah A.Y., Hashemi N. et al. Longterm survivorship in patients (pts) with metastatic renal cell cancer (mRCC): a retrospective study from the MD Anderson Cancer Center (MDACC). American Society of Clinical Oncology. February 26–28, 2015. Orlando, FL. Abstract 510, poster H22.
5. Ljungberg B., Bensalah K., Bex A. et al. Volpe Guidelines on renal cell cancer. European Association of Urology, 2018. Available at: http://www.uroweb.org/.
6. Motzer R.J., Hutson T.E., Tomczak P. et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl JMed 2007;356(2):115–24. DOI: 10.1056/NEJMoa065044. PMID: 17215529.
7. Sternberg C.N., Davis I.D., Mardiak J. et al. Pazopanib in locally advanced or metastatic renal cell carcinoma: Results of a randomized phase III trial. J Clin Oncol 2010;28(6):1061–8. DOI: 10.1200/JCO.2009.23.9764. PMID: 20100962.
8. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: kidney cancer, 2018. Available at: http://www.nccn.org/.
9. Rini B.I., Small E.J. Biology and clinical development of vascular endothelial growth factor-targeted therapy in renal cell carcinoma. J Clin Oncol 2005;23(5):1028–43. DOI: 10.1200/JCO.2005.01.186. PMID: 15534359.
10. Cancer Genome Atlas Research Network. Comprehensive molecular characterization of clear cell renal cell carcinoma. Nature 2013;499(7456):43–9. DOI: 10.1038/nature12222. PMID: 23792563.
11. Baldewijns M.M., van Vlodrop I.J., Vermeulen P.B. et al. VHL and HIF signalling in renal cell carcinogenesis. J Pathol 2010;221(2):125–38. DOI: 10.1002/path.2689. PMID: 20225241.
12. Nakaigawa N., Yao M., Baba M. et al. Inactivation of von Hippel–Lindau gene induces constitutive phosphorylation of MET protein in clear cell renal carcinoma. Cancer Res 2006;66(7):3699–705. DOI: 10.1158/0008-5472.CAN-05-0617. PMID: 16585196.
13. Boysen G., Bausch-Fluck D., Thoma C.R. et al. Identification and functional characterization of pVHL-dependent cell surface proteins in renal cell carcinoma. Neoplasia 2012;14(6):535–46. PMID: 22806541.
14. Gibney G.T., Aziz S.A., Camp R.L. et al. c-Met is a prognostic marker and potential therapeutic target in clear cell renal cell carcinoma. Ann Oncol 2013;24(2):343–9. DOI: 10.1093/annonc/mds463. PMID: 23022995.
15. Zhou L., Liu X.D., Sun M. et al. Targeting MET and AXL overcomes resistance to sunitinib therapy in renal cell carcinoma. Oncogene 2016;35(21):2687–97. DOI: 10.1038/onc.2015.343. PMID: 26364599.
16. Abraham R.T., Gibbons J.J. The mammalian target of rapamycin signaling pathway: twists and turns in the road to cancer therapy. Clin Cancer Res 2007;13(11):3109–14. DOI: 10.1158/1078-0432.CCR-06-2798. PMID: 17545512.
17. Hay N., Sonenberg N. Upstream and downstream of mTOR. Genes Dev 2004;18(16):1926–45. DOI: 10.1101/gad.1212704. PMID: 15314020.
18. Lenvima (lenvatinib) [package insert]. Woodcliff Lake, NJ: Eisai Inc., 2016.
19. Yamamoto Y., Matsui J., Matsushima T. et al. Lenvatinib, an angiogenesis inhibitor targeting VEGFR/FGFR, shows broad antitumor activity in human tumor xenograftmodels associated with microvessel density and pericyte coverage. Vasc Cell 2014;6:18. DOI: 10.1186/2045-824X-6-18. PMID: 25197551.
20. Matsuki M., Adachi Y., Ozawa Y. et al. Targeting of tumor growth and angiogenesis underlies the enhanced antitumor activity of lenvatinib in combination with everolimus. Cancer Sci 2017;108(4): 763–71. DOI: 10.1111/cas.13169. PMID: 28107584.
21. Opdivo (nivolumab) [package insert]. Princeton, NJ: Bristol-Myers Squibb Company, 2016.
22. Ohaegbulam K.C., Assal A., Lazar-Molnar E. et al. Human cancer immunotherapy with antibodies to the PD-1 and PD-L1 pathway. Trends Mol Med 2015;21(1):24–33. DOI: 10.1016/j.molmed.2014.10.009. PMID: 25440090.
23. Motzer R.J., Escudier B., Oudard S. et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet 2008;372(9637):449–56. DOI: 10.1016/S0140-6736(08)61039-9. PMID: 18653228.
24. Rini B.I., Escudier B., Tomczak P. et al. Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial. Lancet 2011;378(9807):1931—9. DOI: 10.1016/S0140-6736(11)61613-9. PMID: 22056247.
25. Motzer R.J., Escudier B., McDermott D.F. et al. Nivolumab versus everolimus in advanced renal-cell carcinoma. N Engl JMed 2015;373(19):1803–13. DOI: 10.1056/NEJMoa1510665. PMID: 26406148.
26. Choueiri T.K., Escudier B., Powles T. et al. Cabozantinib versus everolimus in advanced renal-cell carcinoma. N Engl J Med 2015;373(19):1814–23. DOI: 10.1056/NEJMoa1510016. PMID: 26406150.
27. Motzer R.J., Hutson T.E., Glen H. et al. Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, openlabel, multicentre trial. Lancet Oncol 2015;16(15):1473–82. DOI: 10.1016/S1470-2045(15)00290-9. PMID: 26482279.
28. Motzer R.J., Escudier B., Oudard S. et al. Phase 3 trial of everolimus for metastatic renal cell carcinoma: final results and analysis of prognostic factors. Cancer 2010;116(18):4256–65. DOI: 10.1002/cncr.25219. PMID: 20549832.
29. Motzer R.J., Escudier B., Tomczak P. et al. Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial. Lancet Oncol 2013;14(6):552–562. DOI: 10.1016/S1470-2045(13)70093-7. PMID: 23598172.
30. Choueiri T.K., Escudier B., Powles T. et al. Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial. Lancet Oncol 2016;17(7):917–27. DOI: 10.1016/S14702045(16)30107-3. PMID: 27279544.
31. Motzer R.J., Hutson T.E., Ren M. et al. Independent assessment of lenvatinib plus everolimus in patients with metastatic renal cell carcinoma. Lancet Oncol 2016;17(1):e4–5. DOI: 10.1016/S14702045(15)00543-4. PMID: 26758760.
32. Fisher R., Larkin J. Individualising treatment choices in a crowded treatment algorithm. EJC Suppl 2013;11(2):160–8. DOI: 10.1016/j.ejcsup.2013.07.019. PMID: 26217125.
33. Bottsford-Miller J.N., Coleman R.L., Sood A.K. Resistance and escape from antiangiogenesis therapy: clinical implications and future strategies. J Clin Oncol 2012;30(32):4026–34. DOI: 10.1200/JCO.2012.41.9242. PMID: 23008289.
34. Gerber P.A., Hippe A., Buhren B.A. et al. Chemokines in tumor associated angiogenesis. Biol Chem 2009;390(12):1213–23. DOI: 10.1515/BC.2009.144. PMID: 19804363.
35. Adelaiye R., Ciamporcero E., Miles K.M. et al. Sunitinib dose escalation overcomes transient resistance in clear cell renal cell carcinoma and is associated with epigenetic modifications. Mol Cancer Ther 2015;14(2):513–22. DOI: 10.1158/15357163.MCT-14-0208. PMID: 25519701.
36. Hu-Lowe D.D., Zou H.Y., Grazzini M.L, et al. Nonclinical antiangiogenesis and antitumor activities of axitinib (AG-013736), an oral, potent, and selective inhibitor of vascular endothelial growth factor receptor tyrosine kinases; 1, 2, 3. Clin Cancer Res 2008;14(22):7272–83. DOI: 10.1158/1078-0432.CCR-08-0652. PMID: 19010843.
37. Sonpavde G., Hutson T.E., Rini B.I. Axitinib for renal cell carcinoma. Expert Opin Investig Drugs 2008;17(5):741–8. DOI: 10.1517/13543784.17.5.741. PMID: 18447599.
38. Abrams T.J., Lee L.B., Murray L.J. et al. SU11248 inhibits KIT and platelet-derived growth factor receptor beta in preclinical models of human small cell lung cancer. Mol Cancer Ther 2003;2(5):471–8. PMID: 12748309.
39. Rixe O., Bukowski R.M., Michaelson M.D. et al. Axitinib treatment in patients with cytokine-refractory metastatic renal-cell cancer: a phase II study. Lancet Oncol 2007;8(11):975–84. DOI: 10.1016/S1470-2045(07)70285-1. PMID: 17959415.
40. Cella D., Escudier B., Rini B.I. et al. Patient-reported outcomes (PROs) in a phase III AXIS trial of axitinib versus sorafenib as second-line therapy for metastatic renal cell carcinoma (mRCC). American Society of Clinical Oncology Annual Meeting. June 3–7, 2011. Chicago, IL. J Clin Oncol 2011:29(suppl):abstract 4505.
41. Rini B.I., de La Motte Rouge T., Harzstark A. et al. Five-year survival in patients with cytokine-refractory metastatic renal cell carcinoma treated with axitinib. Clin Genitourin Cancer 2013;11(2):107–14. DOI: 10.1016/j.clgc.2012.12.004. PMID: 23391371.
42. Rixe O., Dutcher J., Motzer R. et al. Diastolic blood pressure (dBP) and pharmacokinetics (PK) as predictors of axitinib efficacy in metastatic renal cell cancer (mRCC). American Society of Clinical Oncology (ASCO). May 29–June 2, 2009. Chicago, IL. J Clin Oncol 2009;27(suppl): abstract 5045.
43. Rini B.I., Melichar B., Fishman M.N. et al. Axitinib dose titration: analyses of exposure, blood pressure and clinical response from a randomized phase II study in metastatic renal cell carcinoma. Ann Oncol 2015;26(7):1372–7. DOI: 10.1093/annonc/mdv103. PMID: 25701454.
44. Bracarda S., Bamias A., Casper J. et al. Optimizing axitinib treatment selection following first-line sunitinib in metastatic renal cell carcinoma. American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium. February 8–10, 2018. San Francisco, CA. Poster 589.
Review
For citations:
Alekseev B.Ya., Shevchuk I.M., Kaprin A.D. Individual approach in choosing second-line targeted therapy for metastatic renal cell carcinoma. Cancer Urology. 2018;14(2):68-78. (In Russ.) https://doi.org/10.17650/1726-9776-2018-14-2-68-78
Views:
695
Email this article 